Drug Trial Radar · NCT06258408
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Dec 29, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Broadenbio Ltd., Co.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.
Conditions
- Advanced Solid Tumor
Interventions
BB102 tabletDrug
BB102 tablets will be administered orally once daily(QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities (DLTs)Time frame: Single dose to the end of Cycle 1 (each cycle is 21 days)
- Number of subjects with adverse events (AEs) and serious adverse events (SAEs)Time frame: From screening (Day -28 to Day -1) through up to 12 months or until disease progression
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.